Even as Celgene reportedly considers buying CAR-T player Juno Therapeutics, Novartis has its own plans to keep a leadership position in the field. On Wednesday, the drugmaker announced that Kymriah won regulatory milestones on both sides of the Atlantic as it seeks to grow its prospects with the cutting-edge technology. 116 more words
Tags » Novartis
Why didn't the anti-CD19 CAR-T immunotherapies from Novartis or Kite suffer from neurotoxicity adverse events as the ones from Juno did?
The most uplifting science stories of 2017
A few bright points throughout the year.
By Rachel Feltman 4 hours ago
*** begin quote *** 176 more words
SAN FRANCISCO (AP) — A sharply divided California Supreme Court ruled Thursday that pharmaceutical companies can be held liable for warning labels on generic versions of drugs they once made even after they’ve sold the drugs to other companies and stopped manufacturing them. 517 more words
By THÉRÈSE MARGOLIS
In August, the U.S. Food and Drug Administration (FDA) approved the first-ever gene-altering treatment for a rare form of childhood leukemia.
This milestone medical breakthrough allows scientists to genetically modify a patient’s own cells to fight cancer, turning them into a “living drug.” 581 more words